CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 125 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $200,220,000 | -52.8% | 30,568 | -52.1% | 0.14% | -48.6% |
| Q3 2020 | $424,403,000 | -42.0% | 63,820 | -27.4% | 0.28% | -63.1% |
| Q2 2020 | $732,007,000 | +8.6% | 87,876 | 0.0% | 0.75% | -42.7% |
| Q1 2020 | $674,009,000 | -7.7% | 87,876 | 0.0% | 1.32% | +46.6% |
| Q4 2019 | $730,250,000 | +83.0% | 87,876 | +62.5% | 0.90% | +193.1% |
| Q3 2019 | $399,000,000 | -66.8% | 54,065 | -49.5% | 0.31% | -42.6% |
| Q2 2019 | $1,200,540,000 | +11.7% | 107,000 | +7.0% | 0.53% | +1.9% |
| Q1 2019 | $1,075,000,000 | +42.4% | 100,000 | +100.0% | 0.52% | +18.1% |
| Q4 2018 | $755,000,000 | +46.3% | 50,000 | +79.2% | 0.44% | +173.5% |
| Q3 2018 | $516,150,000 | +1.7% | 27,900 | +25.7% | 0.16% | -26.4% |
| Q2 2018 | $507,492,000 | -0.9% | 22,200 | +23.3% | 0.22% | +42.9% |
| Q1 2018 | $512,100,000 | +169.5% | 18,000 | +100.0% | 0.15% | +161.0% |
| Q4 2017 | $189,990,000 | – | 9,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
| VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
| Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
| BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
| Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
| Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
| VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
| Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
| Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |